What do the CF patients think about the VX-809/Kalydeco combo?
I would like to share this anecdote with Vertex investors. A few months ago I participated in the care of a young adult with CF. This patient was extremely knowledgeable about her disease. She knew her genotype, homozygous F508del, and was planning to get into the phase III trial for VX-809/Kalydeco. It is difficult to describe the excitement and hope this patient and her family showed for the success of this combination therapy. We may all be concerned about the money we are wagering on the outcome of this phase III trial but these patients are willing to bet their health and lives on it.